Other trials include phase I study (NCT01376505) on a vaccine composed of two HER2 peptides: MVF-HER-2(597–626) and MVF-HER-2 (266–296) tested in different metastatic tumors, including OC; a study on ID-LV305 vaccine, consisting of lentiviral vector targeting DCs, and containing sequences encoding the NY-ESO-1 antigen (NCT02122861); a NCT02387125 trial on CMB305, a combination product composed of a cancer vaccine containing an NY-ESO-1 antigen (LV305) and glucopyranosyl adjuvant in lipid emulsion (G305). The gene discussed is ERBB2; the disease is cancer.